Dose-response analysis of effects of tibolone on climacteric symptoms

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 109, Issue 10, 2002, Pages 1109-1114

  Landgren, M B ^a   Coelingh Bennink, H J T ^b   Helmond, F A ^c,e   Engelen, S ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NV Organon   (Netherlands)

^c Clinical Development Department   (Netherlands)

^d NV Organon   (Netherlands)

^e International Marketing   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIBOLONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FINLAND; HOT FLUSH; HUMAN; MEDICAL RECORD; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NETHERLANDS; NORWAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SWEATING; SWEDEN; VAGINA BLEEDING;

ADULT; CLIMACTERIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGEN RECEPTOR MODULATORS; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NORPREGNENES; SWEATING; UTERINE HEMORRHAGE;

EID: 0036803306     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-0328(02)02920-8     Document Type: Article

References (12)

1. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 76:2001;231-238.
2. Moore R.A. Livial: a review of clinical studies. Br J Obstet Gynaecol. 106(Suppl 19):1999;1-21.
3. Egarter C., Huber J., Leikermoser Ret al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas. 23:1996;55-62.
4. Siseles N.O., Halperin H., Benencia HJet al. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas. 21:1995;201-210.
5. Crona N., Samsioe G., Lindberg U-B, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14. Comparative study with oestradiol valerate and placebo. Maturitas. 9:1988;303-308.
6. Hammar M., Christau S., Nathorst-Böös J., Rud T., Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 105:1998;904-911.
7. Bjarnason N.H., Bjarnason K., Haarbo J., Rosenquist C., Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 81:1996;2419-2422.
8. Berning B., Kuijk C van, Kuiper J.W., Coelingh Bennink H.J.T., Kicovic P.M., Fauser BCJM Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone. 19:1996;395-399.
9. Gallagher J.C., Baylink D.J., Freeman R., McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose finding studies. J Clin Endocrinol Metab. 86:2001;4717-4726.
10. Archer DF, Pickar JH, Bottiglioni F for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-692.
11. Archer D.F., Dorin M., Lewis V., Schneider D.L., Pickar J.H. Effect of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 75:2001;1080-1087.
12. Lindsay R., Hart D.M., Kraszewski A. A prospective, double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. BMJ. 280:1980;1207-1209.